|Bid||52.00 x 2200|
|Ask||52.35 x 2200|
|Day's Range||50.36 - 53.04|
|52 Week Range||38.94 - 86.95|
|Beta (5Y Monthly)||1.60|
|PE Ratio (TTM)||13.92|
|Earnings Date||Nov 01, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||95.30|
Subscribe to Yahoo Finance Plus to view Fair Value for CRSP
It's easy to see why investors might assume that early-stage gene-editing companies like CRISPR Therapeutics (NASDAQ: CRSP) are too inscrutable to approach. In fact, smart investors know (at least) three key things about this business, and you should too -- especially if you're considering purchasing shares sometime soon. CRISPR has a few partners, but its most important one by far is Vertex Pharmaceuticals (NASDAQ: VRTX).
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $50.47, moving -0.55% from the previous trading session.
Gene editing stocks present themselves as one of the more lucrative investments in the healthcare sector. Gene editing, a revolutionary take on the science of genetic engineering, has the potential to countless lives around the globe. By introducing genetic material into cells, scientists can correct genetic abnormalities in a way never seen before. With the potential for vast improvements, gene therapy and gene editing are promising modern biotechnology forms.InvestorPlace - Stock Market News,